DCM
ASBPW

Difesa Capital Management’s Aspire Biopharma Warrant ASBPW Stock Holding History

Difesa Capital Management’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-75,000
Closed -$3.13K – 75
2023
Q1 		$3.13K Hold
75,000
– – ﹤0.01% 178
2022
Q4 		$5.99K Hold
75,000
– – ﹤0.01% 158
2022
Q3 		$8K Hold
75,000
– – ﹤0.01% 166
2022
Q2 		$13K Buy
+75,000
New +$16.3K 0.01% 168

Other funds holding ASBPW

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.97% 1-Year Est. Return

Difesa Capital Management's ASBPW Position: Q2 2023 in Review

Difesa Capital Management sold out of Aspire Biopharma Warrant (ASBPW) in Q2 2023, closing a stake of 75,000 shares — an estimated $3.13K sold.

Difesa Capital Management first reported a position in ASBPW in Q2 2022 and held it in 4 quarters. The position peaked at $13K in Q2 2022. 40 funds tracked by Wall St. Rank hold ASBPW as of Q2 2023.

  • Difesa Capital Management reported no remaining Aspire Biopharma Warrant position as of Q2 2023 after selling out during the quarter.
  • Difesa Capital Management sold 75,000 Aspire Biopharma Warrant shares in Q2 2023, an estimated $3.13K.
  • Difesa Capital Management first reported a position in Aspire Biopharma Warrant in Q2 2022 and held it in 4 quarters.
  • Difesa Capital Management's Aspire Biopharma Warrant position peaked at $13K in Q2 2022.
  • 40 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q2 2023.

Based on Difesa Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.